Breaking Canadian GLP-1 news
GLP-1 News — Page 7
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Where are you in your GLP-1 journey?
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Provincial Coverage of Generic Semaglutide Uncertain After G7-First Approval
Canada became the first G7 country to approve generic semaglutide, but provincial drug plan coverage remains uncertain and varies by province.
Wegovy Pricing Snapshot: Retail $400–$570, Generic Seen Summer 2026
Teletest pegs Wegovy at $400–$570/month in Canada with a generic projected for summer 2026 at $40–$160, while employer coverage data shows narrow access.
Generic Semaglutide Starts at 75% of List Price Under pCPA Rules
Canada's generic pricing framework starts Dr. Reddy's semaglutide at 75% of Ozempic's $228 four-week list price, dropping to 35% with three approved makers.
Generic Semaglutide Filing Dates: How Long Apps Have Waited
Health Canada's generic submissions tracker and Globe and Mail reporting reveal generic semaglutide applications dating back to February 2024 still under review.
Felix Publishes Generic Semaglutide Price Tiers: $112-$240 Per Pen
Telehealth provider Felix outlines a tiered generic semaglutide pricing forecast ranging from $240 down to $112 per pen as more competitors enter Canada's market.
Alberta Blue Cross: GLP-1 Plan Spend Won't Drop Despite Generics
Alberta Blue Cross's 2026 pipeline report says GLP-1 plan spending is unlikely to decline even as a semaglutide generic is expected mid-2026.
CDA Draft: Cover Mounjaro With 25-49% Discount at Higher Doses
Canada's Drug Agency draft report recommends public plans cover Mounjaro for Type 2 diabetes if Eli Lilly grants 25-49% discounts at higher dosages.
Ozempic Tops Canadian Public Drug Spending at $807M: CIHI
Ozempic accounted for $807 million of the $20.1 billion spent on public drug plans across Canada, according to CIHI data released in March 2026.
Health Canada Pausing Generic Semaglutide Reviews, Spokesperson Confirms
Health Canada confirms it pauses generic semaglutide reviews when data is missing, with the clock stopping while manufacturers respond to information requests.
Pharmacy Expert Projects $100/Month Generic Semaglutide in Canada
University of Toronto pharmacy expert Mina Tadrous estimates Canadian generic semaglutide could land near $100 monthly once enough approved versions reach pharmacies.
Endoscopic Procedure Shows Promise for Patients Stopping Tirzepatide
Interim trial data show duodenal mucosal resurfacing helped tirzepatide patients retain over 80% of weight loss after stopping the drug, Reuters reports.
Sandoz CEO Calls Canada World's Second-Largest GLP-1 Market
Sandoz CEO Richard Saynor describes Canada as the world's second-largest GLP-1 market, raising cross-border supply concerns as generics near approval.
TrumpRx GLP-1 Deal Unlikely to Lower Canadian Prices, Experts Say
US TrumpRx program starts GLP-1 prices at US$350, dropping to US$245 over two years, but Canadian prices are already lower and generics loom.
Quebec Public Insurance Declines to Cover Wegovy, Citing Cost
Quebec's health research institute says Wegovy's cost is too high and benefits uncertain, keeping the Novo Nordisk semaglutide pen off the province's public formulary.
Canadians Battle Insurers for Semaglutide Coverage Amid Generic Delay
CTV News reports Canadians are still fighting insurers to cover Ozempic as generic semaglutide remains unapproved more than three months after patent expiry.
Apotex Has Three Separate Generic Semaglutide Filings in Canada
Apotex has filed three separate generic semaglutide applications with Health Canada in January, April and November 2025, the Globe and Mail reports.
Oldest Generic Semaglutide Filing Dates to February 2024
Health Canada's generic semaglutide queue includes applications filed as early as February 2024, with nine submissions pending and Apotex holding three 2025 filings.
Sandoz Eyes End-of-June Canadian Launch for Unbranded Semaglutide
Sandoz told Reuters unbranded Ozempic could launch in Canada by end of June, as generic semaglutide rolls out across India, China, Brazil and Turkey.
Canadian Patients, Doctors Frustrated by Generic Semaglutide Delay
Over three months after Canada's semaglutide patent expired, none of the nine generic applications at Health Canada have been approved, frustrating patients.
Apotex Wins US Tentative Nod for Generic Semaglutide, Canada Waits
Apotex secured tentative FDA approval for generic semaglutide developed with Orbicular, while three of its Canadian applications remain under Health Canada review.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada